- 07/31/2018
- eisai signs collaboration agreement for anti-obesity agent lorcaserin in china to cy biotech
- 07/31/2018
- eisai and merck & co., inc., kenilworth, n.j., u.s.a. announce u.s. fda grants breakthrough therapy designation for lenvima® in combination with keytruda®
- 07/26/2018
- 07/26/2018
- eisai and biogen present detailed results from phase ii clinical study of elenbecestat in mci and mild to moderate alzheimer’s disease at alzheimer’s association international conference (aaic) 2018
- 07/19/2018
- latest data on eisai’s alzheimer’s disease / dementia pipeline to be presented at alzheimer’s association international conference (aaic) 2018
- 06/21/2018
- abbvie and eisai announce the launch of humira® for subcutaneous injection 20 mg syringe 0.2 ml, a new pediatric formulation of humira®
- 06/20/2018
- join hands to make a win-win situation -- eisai china launches its first liver reserve function testing device in china market
- 06/04/2018
- eisai and merck & co., inc., kenilworth, n.j., u.s.a. announce data at 2018 asco annual meeting from investigational studies of lenvima® and keytruda® combination therapy in four different tumor types
- 05/31/2018
- u.s. fda designates for priority review eisai’s supplemental new drug application for antiepileptic drug fycompa® as treatment for pediatric patients with epilepsy
- 05/29/2018
- eisai china won the “best hr teams in greater china” of hroot awards 2018
